Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 5Phase 1 3

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 3Neoplasms 1Hormone-Refractory Prostate Cancer 1Adenocarcinoma of the Prostate 1

Interventions

Cyclophosphamide 297Cisplatin 297Paclitaxel 258Radiotherapy 253Fluorouracil 234Carboplatin 234Docetaxel 231Doxorubicin 212Dexamethasone 164Gemcitabine 155Vincristine 143Etoposide 133Leucovorin 132Capecitabine 129Bevacizumab 129Prednisone 124Rituximab 118Methotrexate 117Cytarabine 108Filgrastim 99Trastuzumab 98Oxaliplatin 96pembrolizumab 81Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Nivolumab 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Completed × sipuleucel-T × Clear all
NCT03686683 2024-10-08

ProVent

Dendreon

Phase 3 Completed
532 enrolled 14 charts
Genitourinary

Adenocarcinoma of the Prostate

NCT00779402 2018-01-29

PROTECT

Dendreon

Phase 3 Completed
176 enrolled 14 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00005947 2010-11-01

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Dendreon

Phase 3 Completed
127 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT01133704 2010-09-08

Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer

Dendreon

Phase 3 Completed
98 enrolled 9 charts
Genitourinary

Hormone-Refractory Prostate Cancer

NCT00065442 2010-09-06

ProvengeĀ® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Dendreon

Phase 3 Completed
512 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔